Recommendations of the Polish Society of Oncological Surgery and Polish Association of Surgeons Prophylaxis and Antithrombotic Treatment in Patients with Malignant Neoplasms: Based on the American College of Chest Physicians (ACCP) guidelines from 2004, Polish Consensus Conference, Cracow 2005, and Recommendations of the Polish Society of Oncological Surgery - 2007

• Authors: Anna Fijałkowska , Andrzej Szawłowski , Marek Wojtukiewicz , Krystyna Zawilska
• Languages of publication: EN

Abstracts

EN

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2008
• Volume: 80
• Issue: 5
• Pages: 288-293

Dates

published

1 - 5 - 2008

online

9 - 6 - 2008

Contributors

author

Anna Fijałkowska

• Department of Internal Medicine and Thoracic Diseases, Institute of Tuberculosis and Pulmonary Diseases, Warsaw

author

Andrzej Szawłowski

• National Consultant in Oncological Surgery, Department of Upper Alimentary Tract Neoplasms, Institute of Oncology, M. Skłodowska-Curie in Warsaw

author

Marek Wojtukiewicz

• Department of Chemotherapy, Regional Oncological Center, Białystok

author

Krystyna Zawilska

• Department of Hematology and Proliferative Diseases of the Hematopoietic System, K. Marcinkowski Medical University, Poznań

References

• Torbicki A, Fijałkowska A, Łopaciuk S: i wsp.: Zasady profilaktyki zakrzepowo-zatorowej w chirurgii onkologicznej. W: Szawłowski AW, Szmidt J (red.) Zasady diagnostyki i chirurgicznego leczenia nowotworów w Polsce. Wyd. I, Fundacja Polski Przegląd Chirurgiczny. Warszawa 2003; 23-28.
• Bergqvist D, Angeli G, Cohen AT et al.: Duration of Prophylaxis Against Venous Thromboembolism With Enoxaparin After Surgery for Cancer. N Engl J Med 2002; 346(13): 975-80.
• Geerts WH, Heit JA et al.: Prevention of venous thormboembolism: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004; 126(3 Suppl.): 338S-400S.
• Zawilska K, Brożek J, Jaesche R: i wsp.: Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej - aktualizacja 2005. Medycyna Praktyczna 2005; supl. 6: 9-56.
• Fijałkowska A, Szawłowski A, Wojtukiewicz M, Zawilska K: Profilaktyka i przeciwzakrzepowe leczenie u chirurgicznych pacjentów z nowotworami złośliwymi - Rekomendacje Polskiego Towarzystwa Chirurgii Onkologicznej. Nowotwory 2007; 57 (supl. 2): 53-59.
• Szawłowski AW: Kliniczny problem powikłań zakrzepowo-zatorowych w onkologii. Nowotwory- J. Oncol 2005; 55: 457-62.
• Rasmussen MS, Jorgensen LN, Wille-Jorgensen P et al.: Prolonged Prophylaxis With Dalteparin to Prevent Late Thromboembolic Complications in Patients Undergoing Major Abdominal Surgery: a Multicenter randomized Open-Label Study. J Thromb Haemost 2006; 4(11): 2384-90.[Crossref][PubMed]
• Bergqvist D, Burmark US, Flordal PA et al.: Low-Molecular Weight Heparin Started Before Surgery As Prophylaxis Against Deep Vein Thrombosis: 2500 Versus 5000 XaI Units in 2070 Patients. Br J Surg 1995; 82(4): 496-501.
• Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin for Prevention of Deep Vein Thrombosis in Elective Cancer Surgery: a Double- Blind Randomized Multicentre Trial With Venographic Assessment. ENOXACAN Study Group. Br J Surg 1997; 84(8): 1099-1103.
• Geerts WH, Pineo GF, Heit JA et al.: Prevention of Venouus Thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 125 (3 Suppl.): 338S-400S.
• Agnelli G, Bergqvist D, Cohen AT et al.: Randomized Clinical Trial of Postoperative Fondaparinux Versus Perioperatitive Dalteparin for Prevention of Venous Thromboembolism in High-Risk Abdominal Surgery. Br J Surg 2005; 92(10): 1212-20.
• Goldhaber SZ, Dunn K, MacDougall RC: New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more by prophylaxis failure than by withholding treatment. Chest 2000; 118: 1680-84.
• Bouthier J: The venous thrombotic risk in non-surgical patients. Drugs 1996; Suppl. 7: 16-28.[Crossref]
• Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21: 1301-36.[PubMed]
• Lee AY, Levine MN, Baker RI et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
• Lee AY, Levine MN: Venous thromboembolism and cancer: risk and outcomes. Circulation 2003; 107: 117-21.
• Heit JA, Mohr DN, Silverstein MD et al.: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-68.
• Lee AY et al.: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous hromboembolism. J Clin Oncol 2005; 23: 2123-29.[Crossref]
• Haddad TC, Greno EW: Chemotherapy-induced thrombosis. Thrombosis Research 2006; 118: 555-68.[Crossref][PubMed]
• Lyman GH, Khorana AA, Falanga A et al.: American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.[Crossref][PubMed][WoS]
• Bennett CL, Silver SM, Djulbegovic B et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia JAMA 2008; 299: 914-24.
• Noble SIR, Hood K, Finlay IG: The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliative Medicine 2007; 21: 473-76.[PubMed][WoS][Crossref]
• Gross PL, Witz JI: New anticoagulants for treatment of venous thromboembolism Arterioscler. Thromb Vasc Biol 2008; 28; 380-86.[Crossref]
• Lee AY, Rickles FR, Julian JA et al.: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-29.[Crossref][PubMed]

Identifiers

DOI

10.2478/v10035-008-0038-x